Elucidation of the interactions between SARS-CoV-2 Spike protein and wild and mutant types of IFITM proteins by *in silico* methods

Nazli Irmak Giritlioglu^{1*}, Gizem Koprululu Kucuk^{2,3}

¹Yildiz Technical University, Graduate School of Science and Engineering, Department of Molecular Biology and Genetics, Istanbul/TURKEY.

²Istanbul Sisli Vocational School, Radiotherapy Program, Istanbul/TURKEY.

³Yeditepe University, Graduate School of Natural and Applied Sciences, Department of Biotechnology, Istanbul/TURKEY.

ABSTRACT

COVID-19 is a viral disease that has been a threat to the whole world since 2019. Although effective vaccines against the disease have been developed, there are still points to be clarified about the mechanism of SARS-CoV-2, which is the causative agent of COVID-19. In this study, we determined the binding energies and the bond types of complexes formed by open (6VYB) and closed (6VXX) forms of the Spike protein of SARS-CoV-2 and wild and mutant forms of IFITM1, IFITM2, and IFITM3 proteins using the molecular docking approach. First, all missense SNPs were found in the NCBI Single Nucleotide Polymorphism database (dbSNP) for IFITM1, IFITM2, and IFITM3 and analyzed with SIFT, PROVEAN, PolyPhen-2, SNAP2, Mutation Assessor, and PANTHER cSNP web-based tools to determine their pathogenicity. When at least four of these analysis tools showed that the SNP had a pathogenic effect on the protein product, this SNP was saved for further analysis. Delta delta G (DDG) and protein stability analysis for amino acid changes were performed in the web-based tools I-Mutant, MUpro, and SAAFEC-SEQ. The structural effect of amino acid change on the protein product was made using the HOPE web-based tool. HawkDock server was used for molecular docking and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) analysis and binding energies of all complexes were calculated. BIOVIA Discovery Studio program was utilized to visualize the complexes. Hydrogen bonds, salt bridges, and non-bonded contacts between Spike and IFITM protein chains in the complexes were detected with the PDBsum web-based tool. The best binding energy among the 6VYB-IFITM wild protein complexes belong to 6VYB-IFITM1 (-46.16 kcal/mol). Likewise, among the 6VXX-IFITM wild protein complexes, the most negative binding energy belongs to 6VXX-IFITM1 (-52.42 kcal/mol). An interesting result found in the study is the presence of hydrogen bonds between the cytoplasmic domain of the IFITM1 wild protein and the S2 domain of 6VYB. Among the Spike-IFITM mutant protein complexes, the best binding energy belongs to the 6VXX-IFITM2 N63S complex (-50.77 kcal/mol) and the worst binding energy belongs to the 6VXX-IFITM3 S50T complex (4.86 kcal/mol).

The study suggests that IFITM1 protein may act as a receptor for SARS-CoV-2 Spike protein. Assays must be advanced from *in silico* to *in vitro* for the determination of the receptor-ligand interactions between IFITM proteins and SARS-CoV-2.

---

* Corresponding author. nazliirmak.giritlioglu@gmail.com

INTRODUCTION

Coronaviruses are crown-shaped, single strand, positive polarity, and enveloped RNA viruses. The virus that causes COVID-19 is classified as beta coronavirus and belongs to the same subgroup as SARS. Therefore it is called SARS-CoV-2 by International Virus Taxonomy Committee [1–3]. SARS-CoV-2 interacts with angiotensin converter receptor-2 (ACE2) and binds to the cell. It uses Spike protein to binds the human lung epithelial cells. Spike protein has three chains that are A, B, and C; respectively. Spike protein plays a key role in SARS-CoV-2 infection in human cells with these three chains. It is a major antigene for attachment of the virus via ACE2 receptor to the cell [4].

Spike protein consists of two subunits. S1 subunit is responsible for host cell receptor binding and the S2 subunit is responsible for the fusion of host cell membranes. S1 domain binds the receptors and it functions as the receptor-binding domain (RBD) [5,6]. Spike protein RBD provides the Coronaviruses binding to the host human receptors. Two types of Spike protein have been identified. The structures of the SARS-CoV-2 Spike protein were determined by cryogenic electron microscopy and it finds out two different (open and closed) conformations of the receptor-binding site. The open form is called 6VYB and the closed-form is called 6VXX. The SARS-CoV-2 Spike protein must be in the open conformation to interact with ACE2 to initiate viral entry. This open type triggers severe infection [7,8].

Polymorphisms are genetic differences that occur with a frequency greater than 1% in a population [9]. Polymorphisms are not the cause of diseases but may be a cause of susceptibility to disease. The most common type of polymorphism in the human genome is single nucleotide polymorphisms. SNP is the difference of a single nucleotide in the DNA sequence. SNPs have a major effect on disease susceptibility and drug response. If there is a mutation such as SNPs, structural variations, chromosome number, and structural anomalies in an individual; these mutations or anomalies will change protein structure and function [10]. As a result, many diseases occur. In addition, changes in protein structure also affect the response to drugs [11]. Single nucleotide polymorphisms occurring in the structure of the Spike protein cause changes in the structure of the protein. In this case, small changes in conformation and sequence can lead to differences in the affinity of Spike proteins for ACE2 protein [12].

Interferon-induced transmembrane (IFITM) proteins are a family of small membrane proteins with immunological and developmental roles. Five types of IFITM proteins have been identified in humans: IFITM1, IFITM2, IFITM3, IFITM5, and IFITM10 [13]. The interferon-derived transmembrane protein family (IFITM/MIL/Fragilis) genes encode cell-surface proteins that can regulate cell adhesion and influence cell differentiation. IFITM1 and IFITM3 proteins expressed in primordial germ cells (PGCs) are involved in germ cell development, but their specific functions are unclear [14]. IFITM1 and IFITM3 proteins expressed in PGC are involved in germ cell development, but their specific functions are unclear [15]. IFITM1, IFITM2, and IFITM3 proteins are natal immune responses to virus infections. They regulate the fusion of the virus and direct it to lysosomes [16,17]. IFITM3 can affect membrane stiffness and warp to inhibit virus membrane fusion [18]. This action prevents the release of viral particles into the cytoplasm [19].

IFITM proteins are a cofactor for SARS-CoV-2 infection and these are potential targets for therapeutic approaches. Peptides and targeting antibodies that derived from IFITM (especially IFITM1, 2, and 3) have important roles in inhibition of SARS-CoV-2 entry and replication in the few cell types as the host human lung cells, cardiomyocytes, and gut [20]. In this study, we demonstrated the interactions (binding energies of the protein-protein complexes and bond types) of wild and mutant types of IFITM1, IFITM2, and IFITM3 proteins with open and closed forms of SARS-CoV-2 Spike protein by molecular docking approach. The workflow chart of the study can be seen in Figure 1.

MATERIALS AND METHODS

Data extraction and evaluation of the missense SNPs of *IFITM1*, *IFITM2*, and *IFITM3*

NCBI dbSNP (<https://www.ncbi.nlm.nih.gov/snp/>) [21] was utilized for the determination of the missense SNPs on *IFITM1*, *IFITM2*, and *IFITM3* on July 2021. The web-based tools; Sorting Intolerant From Tolerant (SIFT) (https://sift.bii.a-star.edu.sg/www/SIFT_dbSNP.html) [22], Protein Variation Effect Analyzer (PROVEAN) (http://provean.jcvi.org/seq_submit.php) [23], PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) [24], SNAP2 (<https://roslab.org/services/snap2web/>) [25], Mutation Assessor (<http://mutationassessor.org/r3/>) [26,27], and Protein Analysis Through Evolutionary Relationships (PANTHER) coding SNP (cSNP) (<http://www.pantherdb.org/tools/csnpscoreForm.jsp>) [28] tools were used for the first analysis to determine the effects of the missense SNPs. SIFT is a program that predicts the functional effect of an amino acid substitution in a particular protein. If the score provided by the program is ≤ 0.05 , the effect is deleterious; the exact opposite, the score is > 0.05 then the effect is determined as tolerated [29]. The rsIDs of missense SNPs extracted from NCBI dbSNP were pasted into the SIFT4G predictions tool. Besides the effects of amino acid substitutions, SIFT also provides the information of nucleotide changes and amino acid changes as a table caused by missense SNPs. PROVEAN is a web-based tool in which functional effects are determined based on the amino acid sequence of a protein found in any organism. The default score threshold of the PROVEAN Protein tool is -2.5. In the binary classification, if the score is ≤ -2.5 , the effect is deleterious; the score is > -2.5 , the effect is neutral [30]. Amino acid FASTA sequences of *IFITM1*, *IFITM2*, and *IFITM3* proteins were copied from UniProt (<https://www.uniprot.org/>) [31] and inserted into the PROVEAN Protein tool with substitutions. PolyPhen-2 works similarly to PROVEAN. PolyPhen-2 scores differ from 0.0 (benign) to 1.0 (damaging) [32]. SNAP2 is a classifier based on a neural network and utilizes evolutionary information from multiple sequence alignments, predicted structural properties, etc. of the amino acid sequences [33]. Mutation Assessor and PANTHER cSNP tools estimate the effects of the substitutions in the evolutionary base. In the first analysis, if the prediction is possibly damaging (POD), probably damaging (PRD), deleterious (DLT), and/or the functional impacts are low, medium, or high in at least 4 of 6 tools, they were saved for the further analysis. Neutral or benign effects were not considered in the study (Table 1).

DDG determination and structural Analysis of the pathogenic forms of *IFITM1*, *IFITM2*, and *IFITM3* proteins

DDG (or referred to as $\Delta\Delta G$, double changes in Gibbs free energy)s and stability changes of the proteins were determined in the web-based prediction tools: I-Mutant (<http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi>) [34], MUpro (<http://mupro.proteomics.ics.uci.edu/>) [35] and SAAFEC-SEQ (<http://compbio.clemson.edu/SAAFEC-SEQ/#started>) [36]. Default settings (Temperature: 25 °C, pH: 7.0) and the "DDG Value and Binary Classification" option were preferred in I-Mutant. Sequence-based analyses were performed for all pathogenic proteins in the aforementioned tools. If two or three of I-Mutant, MUpro, and SAAFEC-SEQ give the same result, the mutation is considered to make the protein more stable or unstable (Table 2). Also, the HOPE tool was used for structural analysis in terms of size, charge, and physical state of the proteins [37] (Table 3).

Homology modeling of wild and mutant Types of *IFITM1*, *IFITM2*, and *IFITM3* proteins

Amino acid sequences (FASTA format) of wild-type protein products of *IFITM1*, *IFITM2*, and *IFITM3* were obtained from UniProt [31]. UniProt IDs for *IFITM1*, *IFITM2*, and *IFITM3* proteins are P13164, Q01629, and Q01628, respectively. Homology modeling of these proteins was performed via the I-TASSER online server. I-TASSER provides the Confidence (C)-score, estimated TM-score, and estimated RMSD value for each model it creates. The C-score takes a value in the range of [-5,2] and a high C-score indicates high confidence for the related model [38,39]. Also, SWISS-MODEL QMEAN (Qualitative Model Energy Analysis) [40] and ERRAT [41] scores were used for structure

assessment. The quality of the model is low when the QMEAN score is less than -4 [42]. If the ERRAT score is higher than 50, the model can be accepted to be of high quality [43]. Mutant-type proteins were generated with the UCSF Chimera program [44]. Simply the wild-type residues were replaced with the mutant-type residues by entering a specific command (swapaa). Swapaa utilizes the information from a rotamer library for this operation [45].

Molecular docking of protein-protein complexes

Molecular docking was carried out between the open and closed forms of Spike proteins of SARS-CoV-2 and wild and pathogenic mutants of the IFITM1, IFITM2, and IFITM3 proteins. For this purpose, the HawkDock server was used for the prediction and analysis of protein-protein complexes [46]. The PDB ID and chain information of the open and closed forms of the Spike proteins were entered into the server (6VYB:A for open form, 6VXX:A for closed-form) as the receptors. PDB files of wild and mutant types of IFITM1, IFITM2, and IFITM3 proteins were uploaded to the server as ligands. Hawkdock server proposes that the larger proteins be designated as receptors (<http://cadd.zju.edu.cn/hawkdock/>). After molecular docking is complete, Hawkdock presents 100 models for each complex and the scores of the ten of these models with the most negative scores. At this stage, the PDB files of the complexes with the most negative score were saved. MM/GBSA analyzes were performed in the same software and the binding energies were calculated for each complex. The interactions in the protein-protein complexes were visualized with the BIOVIA Discovery Studio 2021 program [47] (Figure 2, Figure 3, and Figure 4) and the H-bond option was selected for the surface display. In addition, all bonds (H-bonds, salt bridges, and non-contact bonds) and the number of these bonds in protein-protein complexes were revealed with the PDBsum online tool (<https://www.ebi.ac.uk/thornton-srv/databases/pdbsum/Generate.html>) [48].

RESULTS AND DISCUSSION

Data extraction and evaluation of the missense SNPs of IFITM1, IFITM2, and IFITM3

There were 1426 SNPs for *IFITM1*, 1834 SNPs for *IFITM2*, and 1584 SNPs for *IFITM3* in NCBI dbSNP on August 2021. Total missense SNP numbers for *IFITM1*, *IFITM2*, and *IFITM3* were 95, 139, and 130 respectively. rsIDs of the SNPs, allele changes, amino acid changes, pathogenicity/functional impact scores, predictions, functional impacts, and preservation times according to information from SIFT, PROVEAN, PolyPhen-2, SNAP2, Mutation Assessor, and PANTHER cSNP were shown in Table S1. 18 SNPs have harmful effects on the protein products of *IFITM1*, *IFITM2*, and *IFITM3* in at least four of the six tools. Among them, the most preserved are rs11552366 (*IFITM1*), rs200528039 (*IFITM1*), and rs371179996 (*IFITM2*) (456 million years). If the preservation is strong, the functional impact of the protein resulting from the variation will be high. Based on the information from whole tools, the most pathogenic missense SNP appears to be rs11552366 (*IFITM1*) (Table 1).

DDG determination and structural analysis of the pathogenic forms of IFITM1, IFITM2, and IFITM3 proteins

According to the evaluation results of I-Mutant, MUpro, and SAAFEC-SEQ; amino acid changes in only two (H57L and H36L) of the 18 mutant proteins were predicted to increase the stability of the proteins (Table 2). Positive DDG values cause mutation to make the protein more stable, while negative values lead to more unstable proteins. The HOPE results showed that the mutant residue in seven (I87T, L41P, P34S, N63S, H3Q, H57L, and H36L) of the 18 mutant proteins had a smaller size compared to the wild-type residue; the mutant residues of the other 11 mutant proteins (Q120H, G74R, E30K, H6Y, V61M, V24M, C84Y, V53M, E20K, S50T, and V90I) were bigger than the wild-type residues. HOPE (Table 3) specified that changes in residue size and hydrophobicity due to mutant residue may affect contact with the lipid membrane. A mutant residue bigger than the wild-type residue may cause bumps. The results indicate that H6Y, N63S, H57L, H36L cause more hydrophobic protein structure. This is in agreement with the I-Mutant and MUpro results, as hydrophobicity can impart stability to mutant proteins. I87T, G74R, C84Y, and P34S lead to the formation of less hydrophobic protein structures, which can make the protein less stable. The reduced hydrophobicity of

the protein means loss of H-bonds, resulting in loss of hydrophobic interactions, it also has a negative effect on protein folding. These results are also compatible with the protein structure analysis tools. Table x also shows that the charges of some mutant residues are different from the charges of wild-type residues. The difference in the charge of the mutant-type residue from that of the wild-type residue can cause repulsions within the protein itself or between the protein and the ligand.

Homology modeling of wild and mutant types of IFITM1, IFITM2, and IFITM3 proteins

As a result of homology modeling evaluation for wild-type protein models provided by I-TASSER, the models with the highest C, ERRAT, and QMEAN scores were selected, therefore the homology models with the most quality are Model 1 for IFITM1, Model 1 for IFITM2, and Model 2 for IFITM3 (Table 4). The C and ERRAT scores appear to be within acceptable ranges, but the QMEAN scores are lower than expected in all models.

Molecular docking of protein-protein complexes

As a result of the docking analysis performed with HawkDock (Table 5), the best binding among the open form of Spike-IFITM (wild) complexes belong to 6VYB-IFITM1 and the binding energy of the complex is -46.16 kcal/mol. This is followed by 6VYB-IFITM3 (-31.63 kcal/mol) and 6VYB-IFITM2 (-22.7 kcal/mol) complexes. The best binding among the close form of the spike (6VXX)-IFITM (wild) complexes belongs to 6VXX-IFITM1 (-52.42 kcal/mol). The binding energies of 6VXX-IFITM3 (wild) and 6VXX-IFITM2 (wild) complexes are -41.29 kcal/mol and -26.67 kcal/mol, respectively.

Bond analysis (H-bond, salt bridge, and non-contact bond) by PDBSum (Table 6 and Table 7) shows that the number of H-bonds between 6VYB and IFITM1/IFITM2/IFITM3 (wild) is equal (two H-bonds). Hydrogen bonds play an important role in determining the three-dimensional structures and the specificity of ligand binding [49,50]. It is reported that H-bonds displace protein-bound water molecules and promote the ligand-binding affinity [51]. The 6VYB-IFITM3 (wild) complex differs from other 6VYB-IFITM (wild) complexes in that it has a salt bridge in between. In terms of non-bonded contact numbers, there are 158 bonds between 6VYB and IFITM2 (wild), while 150 bonds with IFITM3 (wild) and 131 bonds with IFITM1 (wild). Although the number of non-bonded contacts is less in the 6VYB-IFITM3 (wild) complex than other 6VYB-IFITM (wild) complexes, the extra salt bridge may explain the binding energy of the complex being better than the binding energy of the 6VYB-IFITM2 (wild) complex. The difference between the binding energies of the 6VXX-IFITM (wild) complexes emphasized the importance of a large number of non-bonded contacts. There are 197, 144 and 147 non-bonded contacts between protein-protein in the 6VXX-IFITM1 (wild), 6VXX-IFITM2 (wild) and 6VXX-IFITM3 (wild) complexes, respectively. Although the 6VXX-IFITM3 complex has six H-bonds and four salt bridges, the binding energy of the complex is less negative than the 6VXX-IFITM1 (wild) complex. Non-covalent interactions are relatively weak interactions, but their excess may provide a better interaction than H-bonds and salt bridges.

In Spike-IFITM (wild) complexes, the places where H-bonds are formed are different according to the closed and open forms of the Spike. H-bond formation with the S1 domain of the spike is seen in all 6VYB-IFITM (wild) complexes. Only 6VYB-IFITM1 (wild) complex also has H-bond formation of IFITM1 (wild) with S2. There is H-bond formation with both the S1 and S2 in the 6VXX-IFITM3 (wild) complex, while there is only H-bond formation with the S1 in the 6VXX-IFITM1 (wild) complex. There is no H-bond between 6VXX and IFITM2 (wild). Interesting results have emerged regarding the sites where H-bonds are formed, both with the 6VYB-IFITM (wild) and 6VXX-IFITM (wild) complexes. In the 6VYB-IFITM1 complex, binding occurred between the S1 and extracellular

region of IFITM1 and between S2 and the cytoplasmic region of IFITM1. This may indicate that IFITM1 protein acts as a receptor for the Spike protein.

The most negative binding energy belonged to the 6VYB-IFITM1 P34S between the mutant type proteins of IFITM1 and the 6VYB complexes; and showed a little better binding than the wild type of IFITM1. This complex contains two H-bonds at the same positions as the 6VYB-IFITM1 (wild) complex and does not contain salt bridges. This complex contains H-bonds at the same positions as the 6VYB-IFITM1 (wild) complex and does not contain salt bridges. The binding between amino acid 850 (GLU) of S2 and amino acid 36 (HIS) of IFITM1 in one of the cytoplasmic domains in the region may be somewhat restricted by proline, amino acid 34 of wild-type IFITM. Because HOPE results indicated that the new residue (serine) was smaller at this location. In this case, it can be clarified why mutant-type binding is better. There is no 6VXX-IFITM1 (mutant) complex that has a better binding energy value than the 6VXX-IFITM1 (wild) complex.

The number of non-bonded contacts in all of the complexes formed by the mutant type protein of 6VYB and IFITM2 is higher than the non-bonded contacts in the 6VYB-IFITM2 (wild) complex, and therefore the binding energies of all complexes are slightly more negative than the binding energy of the 6VYB-IFITM2 (wild) complex. In the complexes formed by mutant-type proteins of IFITM2 with both 6VYB and 6VXX, the most negative binding energy was observed in the complexes with IFITM2 N63S. The binding energies of 6VYB-IFITM2 N63S and 6VXX-IFITM2 N63S complexes are -25.37 kcal/mol and -50 kcal/mol, respectively.

Among the complexes formed by 6VYB and IFITM3 mutants, the most negative binding energy belongs to the 6VYB-H57L complex (-44.09 kcal/mol). There may be two reasons for this. Compared to the 6VYB-IFITM3 (wild) complex, the number of H-bonds in the 6VYB-H57L complex is 2 times higher (4) and the number of non-bonded contacts is slightly more than double (296). Between the complexes formed by 6VXX and IFITM3 mutants, there is no complex with more negative binding energy than the 6VXX-IFITM3 (wild) complex. Between the complexes formed by 6VXX and IFITM3 mutants, there is no complex with more negative binding energy than the 6VXX-IFITM3 (wild) complex. The 6VXX-IFITM3 (wild) complex has more H-bonds and salt bridges than the 6VXX-IFITM3 mutant complex. An interesting result here is that the binding energy (4.86 kcal/mol) of the 6VXX-S50T complex is positive, making it the worst binding. Unlike other 6VXX-IFITM3 complexes, in the 6VXX-S50T complex, three H-bonds are formed with the first and second amino acids of the signal peptide located at the N-terminus of the Spike protein and the cytoplasmic domain of IFITM3 S50T. It is difficult to say whether this is related to any mechanistic event, since there may also be a binding affinity seen only *in silico*.

CONCLUSION

Although effective vaccines have been developed for COVID-19, there are still points to be clarified about the mechanism of SARS-CoV-2. The mechanisms need to be well known in the development of new inhibitory drugs for the treatment of viral diseases. This study is the only study that offers a molecular docking approach to determine the interaction of both wild and mutant types of IFITM proteins with the Spike protein of SARS-CoV-2. With this study, we propose for the first time that there may be another receptor (IFITM1) for Spike other than ACE2, TMPRSS2 and FURIN. Our study is *in silico*-based and needs to be investigated *in vitro* as well.

REFERENCES

- [1] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G.F. Gao, W. Tan, A Novel Coronavirus from Patients with Pneumonia in China, 2019, <https://doi.org/10.1056/NEJMoa2001017>. 382 (2020) 727–733. <https://doi.org/10.1056/NEJMoa2001017>.
- [2] P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Liu, Y. Chen, X.-R. Shen, X. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.-F. Xiao, Z.-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin, *Nat.* 2020 5797798. 579 (2020) 270–273. <https://doi.org/10.1038/s41586-020-2012-7>.
- [3] M. Cascella, M. Rajnik, A. Aleem, S.C. Dulebohn, R. Di Napoli, Features, Evaluation, and Treatment of Coronavirus (COVID-19), *StatPearls*. (2021). <https://www.ncbi.nlm.nih.gov/books/NBK554776/> (accessed September 3, 2021).
- [4] J. Shang, G. Ye, K. Shi, Y. Wan, C. Luo, H. Aihara, Q. Geng, A. Auerbach, F. Li, Structural basis of receptor recognition by SARS-CoV-2, *Nat.* 2020 5817807. 581 (2020) 221–224. <https://doi.org/10.1038/s41586-020-2179-y>.
- [5] L. F, Structure, Function, and Evolution of Coronavirus Spike Proteins, *Annu. Rev. Virol.* 3 (2016) 237–261. <https://doi.org/10.1146/ANNUREV-VIROLOGY-110615-042301>.
- [6] M.A. Tortorici, A.C. Walls, Y. Lang, C. Wang, Z. Li, D. Koerhuis, G.-J. Boons, B.-J. Bosch, F.A. Rey, R.J. de Groot, D. Veisler, Structural basis for human coronavirus attachment to sialic acid receptors, *Nat. Struct. Mol. Biol.* 2019 266. 26 (2019) 481–489. <https://doi.org/10.1038/s41594-019-0233-y>.
- [7] D. Suárez, N. Díaz, SARS-CoV-2 Main Protease: A Molecular Dynamics Study, *J. Chem. Inf. Model.* (2020). <https://doi.org/10.1021/ACS.JCIM.0C00575>.
- [8] D. Pinto, Y.-J. Park, M. Beltramello, A.C. Walls, M.A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J.B. Case, R.E. Chen, C. Havenar-Daughton, G. Snell, A. Telenti, H.W. Virgin, A. Lanzavecchia, M.S. Diamond, K. Fink, D. Veisler, D. Corti, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, *Nat.* 2020 5837815. 583 (2020) 290–295. <https://doi.org/10.1038/s41586-020-2349-y>.
- [9] Y. Jian, M. Li, A narrative review of single-nucleotide polymorphism detection methods and their application in studies of *Staphylococcus aureus*, *J. Bio-X Res.* 4 (2021) 1–9. <https://doi.org/10.1097/JBR.0000000000000071>.
- [10] D.H. Nawab, The Pharmaceutical Applications of Next Generation Sequencing in Oncology Drug Designing and Development, (2015). <https://doi.org/10.4172/2469-9853.1000116>.
- [11] E. Konaç, G. Üniversitesi, T. Fakültesi, T. Biyoloji, G. Anabilim, A. Ekmekçi, H. İlke Önen, T. Biyoloji Ve Genetik, A. Dalı, T. Ankara, DERLEME GEN POLİMORFİZMİ VE KANSERE YATKINLIK, *Marmara Med. J.* 21 (2008) 282–295.
- [12] L. Y, T.-G. H, S. G, C. X, COVID-19 Infections and Deaths among Connecticut Nursing Home Residents: Facility Correlates, *J. Am. Geriatr. Soc.* 68 (2020) 1899–1906. <https://doi.org/10.1111/JGS.16689>.
- [13] Z. Zhang, J. Liu, M. Li, H. Yang, C. Zhang, Evolutionary Dynamics of the Interferon-Induced Transmembrane Gene Family in Vertebrates, *PLoS One.* 7 (2012) e49265. <https://doi.org/10.1371/JOURNAL.PONE.0049265>.
- [14] T. SS, Y. YL, T. B, L. H, T. PP, IFITM/Mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion, *Dev. Cell.* 9 (2005) 745–756. <https://doi.org/10.1016/J.DEVCEL.2005.10.010>.
- [15] G. MJ, P. S, F. M, D. MS, The Interferon-Stimulated Gene Ifitm3 Restricts West Nile Virus Infection and Pathogenesis, *J. Virol.* 90 (2016) 8212–8225. <https://doi.org/10.1128/JVI.00581-16>.
- [16] S. JS, H. R, H. HH, D. T, T. E, R. CM, P. T, C. K, H. HC, IFITM3 directly engages and shuttles incoming virus particles to lysosomes, *Nat. Chem. Biol.* 15 (2019) 259–268.

- <https://doi.org/10.1038/S41589-018-0213-2>.
- [17] S. KC, L. CC, M. P, M. M, M. RM, D. TM, C. FS, B. AL, M. GB, Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes, *PLoS Pathog.* 15 (2019). <https://doi.org/10.1371/JOURNAL.PPAT.1007532>.
  - [18] L. K, M. RM, Z. YM, G. O, B. B, L. M, D. S, H. Y, L. C, L. JC, G. E, C. FS, L. SL, IFITM proteins restrict viral membrane hemifusion, *PLoS Pathog.* 9 (2013). <https://doi.org/10.1371/JOURNAL.PPAT.1003124>.
  - [19] A. Zani, J.S. Yount, Antiviral Protection by IFITM3 In Vivo, *Curr. Clin. Microbiol. Reports* 2018 54. 5 (2018) 229–237. <https://doi.org/10.1007/S40588-018-0103-0>.
  - [20] C. Prelli Bozzo, R. Nchioua, M. Volcic, L. Koepke, J. Krüger, D. Schütz, S. Heller, C.M. Stürzel, D. Kmiec, C. Conzelmann, J. Müller, F. Zech, E. Braun, R. Groß, L. Wettstein, T. Weil, J. Weiß, F. Diofano, A.A. Rodríguez Alfonso, S. Wiese, D. Sauter, J. Münch, C. Goffinet, A. Catanese, M. Schön, T.M. Boeckers, S. Stenger, K. Sato, S. Just, A. Kleger, K.M.J. Sparrer, F. Kirchhoff, IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro, *Nat. Commun.* 2021 121. 12 (2021) 1–13. <https://doi.org/10.1038/s41467-021-24817-y>.
  - [21] Home - SNP - NCBI, (n.d.). <https://www.ncbi.nlm.nih.gov/snp/>, Accessed: 2021/08/20.
  - [22] P.C. Ng, S. Henikoff, SIFT: Predicting amino acid changes that affect protein function, *Nucleic Acids Res.* 31 (2003) 3812–3814. <https://doi.org/10.1093/nar/gkg509>.
  - [23] Y. Choi, A.P. Chan, PROVEAN web server: A tool to predict the functional effect of amino acid substitutions and indels, *Bioinformatics.* 31 (2015) 2745–2747. <https://doi.org/10.1093/bioinformatics/btv195>.
  - [24] I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork, A.S. Kondrashov, S.R. Sunyaev, A method and server for predicting damaging missense mutations, *Nat. Methods.* 7 (2010) 248–249. <https://doi.org/10.1038/nmeth0410-248>.
  - [25] M. Hecht, Y. Bromberg, B. Rost, Better prediction of functional effects for sequence variants, *BMC Genomics.* 16 (2015) S1. <https://doi.org/10.1186/1471-2164-16-S8-S1>.
  - [26] B. Reva, Y. Antipin, C. Sander, Predicting the functional impact of protein mutations: Application to cancer genomics, *Nucleic Acids Res.* 39 (2011). <https://doi.org/10.1093/nar/gkr407>.
  - [27] B. Reva, Y. Antipin, C. Sander, Determinants of protein function revealed by combinatorial entropy optimization, *Genome Biol.* 8 (2007) R232. <https://doi.org/10.1186/gb-2007-8-11-r232>.
  - [28] H. Tang, P.D. Thomas, PANTHER-PSEP: Predicting disease-causing genetic variants using position-specific evolutionary preservation, *Bioinformatics.* 32 (2016) 2230–2232. <https://doi.org/10.1093/bioinformatics/btw222>.
  - [29] SIFT Help, (n.d.). https://sift.bii.a-star.edu.sg/www/SIFT_help.html, Accessed: 2021/08/20.
  - [30] PROVEAN About, (n.d.). <http://provean.jcvi.org/about.php#:~:text=PROVEAN%20was%20developed%20to%20predict,sequence%20variations%20including%20the%20following>, Accessed: 2021/08/20.
  - [31] T.U. Consortium, A. Bateman, M.-J. Martin, S. Orchard, M. Magrane, R. Agivetova, S. Ahmad, E. Alpi, E.H. Bowler-Barnett, R. Britto, B. Bursteinas, H. Bye-A-Jee, R. Coetzee, A. Cukura, A. Da Silva, P. Denny, T. Dogan, T. Ebenezer, J. Fan, L.G. Castro, P. Garmiri, G. Georgiou, L. Gonzales, E. Hatton-Ellis, A. Hussein, A. Ignatchenko, G. Insana, R. Ishtiaq, P. Jokinen, V. Joshi, D. Jyothi, A. Lock, R. Lopez, A. Luciani, J. Luo, Y. Lussi, A. MacDougall, F. Madeira, M. Mahmoudy, M. Menchi, A. Mishra, K. Moulang, A. Nightingale, C.S. Oliveira, S. Pundir, G. Qi, S. Raj, D. Rice, M.R. Lopez, R. Saidi, J. Sampson, T. Sawford, E. Speretta, E. Turner, N. Tyagi, P. Vasudev, V. Volynkin, K. Warner, X. Watkins, R. Zaru, H. Zellner, A. Bridge, S. Poux, N. Redaschi, L. Aimò, G. Argoud-Puy, A. Auchincloss, K. Axelsen, P. Bansal, D. Baratin, M.-C. Blatter, J. Bolleman, E. Boutet, L. Breuza, C. Casals-Casas, E. de Castro, K.C. Echioukh, E. Coudert, B. Cuhe, M. Doche, D. Dornevil, A. Estreicher, M.L. Famiglietti, M. Feuermann, E. Gasteiger, S. Gehant, V. Gerritsen, A. Gos, N. Gruaz-Gumowski, U. Hinz, C. Hulo, N. Hyka-Nouspikel, F. Jungo, G. Keller, A. Kerhornou, V. Lara, P. Le Mercier, D. Lieberherr, T. Lombardot, X. Martin, P. Masson, A. Morgat, T.B. Neto, S. Paesano, I. Pedruzzi, S.

- Pilbout, L. Pourcel, M. Pozzato, M. Pruess, C. Rivoire, C. Sigrist, K. Sonesson, A. Stutz, S. Sundaram, M. Tognolli, L. Verbregue, C.H. Wu, C.N. Arighi, L. Arminski, C. Chen, Y. Chen, J.S. Garavelli, H. Huang, K. Laiho, P. McGarvey, D.A. Natale, K. Ross, C.R. Vinayaka, Q. Wang, Y. Wang, L.-S. Yeh, J. Zhang, P. Ruch, D. Teodoro, UniProt: the universal protein knowledgebase in 2021, *Nucleic Acids Res.* 49 (2021) D480–D489. <https://doi.org/10.1093/NAR/GKAA1100>.
- [32] PolyPhen-2 score, (n.d.). <https://ionreporter.thermofisher.com/ionreporter/help/GUID-57A60D00-0654-4F80-A8F9-F6B6A48D0278.html#:~:text=The%20PolyPhen%2D%20score%20predicts,%2Dprob%20PolyPhen%2D%20score.,> Accessed: 2021/08/20.
- [33] Snap2 - Rost Lab Open, (n.d.). <https://roslab.org/services/snap2web/>, Accessed: 2021/08/20.
- [34] E. Capriotti, P. Fariselli, R. Casadio, I-Mutant2.0: Predicting stability changes upon mutation from the protein sequence or structure, *Nucleic Acids Res.* 33 (2005) W306. <https://doi.org/10.1093/nar/gki375>.
- [35] J. Cheng, A. Randall, P. Baldi, Prediction of protein stability changes for single-site mutations using support vector machines, *Proteins Struct. Funct. Genet.* 62 (2006) 1125–1132. <https://doi.org/10.1002/prot.20810>.
- [36] G. Li, S.K. Panday, E. Alexov, Saafec-seq: A sequence-based method for predicting the effect of single point mutations on protein thermodynamic stability, *Int. J. Mol. Sci.* 22 (2021) 1–11. <https://doi.org/10.3390/ijms22020606>.
- [37] H. Venselaar, T.A. te Beek, R.K. Kuipers, M.L. Hekkelman, G. Vriend, Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces, *BMC Bioinforma.* 2010 111. 11 (2010) 1–10. <https://doi.org/10.1186/1471-2105-11-548>.
- [38] Z. Y, I-TASSER server for protein 3D structure prediction, *BMC Bioinformatics.* 9 (2008). <https://doi.org/10.1186/1471-2105-9-40>.
- [39] I-TASSER server for protein structure and function prediction, (n.d.). <https://zhanglab.ccmb.med.umich.edu/I-TASSER/about.html> (accessed August 13, 2021).
- [40] P. Benkert, M. Biasini, T. Schwede, Toward the estimation of the absolute quality of individual protein structure models, *Bioinformatics.* 27 (2011) 343–350. <https://doi.org/10.1093/bioinformatics/btq662>.
- [41] C. C, Y. TO, Verification of protein structures: patterns of nonbonded atomic interactions, *Protein Sci.* 2 (1993) 1511–1519. <https://doi.org/10.1002/PRO.5560020916>.
- [42] Help | SWISS-MODEL, (n.d.). <https://swissmodel.expasy.org/docs/help> (accessed August 13, 2021).
- [43] A. Messaoudi, H. Belguith, J. Ben Hamida, Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 β -lactamase, *Theor. Biol. Med. Model.* 10 (2013) 22. <https://doi.org/10.1186/1742-4682-10-22>.
- [44] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, UCSF Chimera - A visualization system for exploratory research and analysis, *J. Comput. Chem.* 25 (2004) 1605–1612. <https://doi.org/10.1002/jcc.20084>.
- [45] swapaa, (n.d.). <https://www.cgl.ucsf.edu/chimera/docs/UsersGuide/midas/swapaa.html> (accessed August 28, 2021).
- [46] G. Weng, E. Wang, Z. Wang, H. Liu, F. Zhu, D. Li, T. Hou, HawkDock: a web server to predict and analyze the protein–protein complex based on computational docking and MM/GBSA, *Nucleic Acids Res.* 47 (2019) W322–W330. <https://doi.org/10.1093/NAR/GKZ397>.
- [47] BIOVIA Discovery Studio Visualizer - Dassault Systèmes, (n.d.). <https://discover.3ds.com/discovery-studio-visualizer-download> (accessed March 30, 2021).
- [48] R.A. Laskowski, J. Jabłońska, L. Pravda, R.S. Vařeková, J.M. Thornton, PDBsum: Structural summaries of PDB entries, *Protein Sci.* 27 (2018) 129. <https://doi.org/10.1002/PRO.3289>.
- [49] S. S, H. VJ, D. S, S. M, Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity assessment, *Prog. Biophys. Mol. Biol.* 116 (2014) 174–186. <https://doi.org/10.1016/J.PBIOMOLBIO.2014.05.006>.

- [50] S. T, F. DG, K. K, Role of the key mutation in the selective binding of avian and human influenza hemagglutinin to sialosides revealed by quantum-mechanical calculations, J. Am. Chem. Soc. 132 (2010) 16862–16872. <https://doi.org/10.1021/JA105051E>.
- [51] G.A. Ross, G.M. Morris, P.C. Biggin, Rapid and Accurate Prediction and Scoring of Water Molecules in Protein Binding Sites, PLoS One. 7 (2012) e32036. <https://doi.org/10.1371/JOURNAL.PONE.0032036>.

FIGURES AND TABLES

Table 1. Evaluation of the missense SNPs of *IFITM1*, *IFITM2*, and *IFITM3* via web-based prediction tools

GENE	SNP	ALLELE CHANGE	AMINO ACID CHANGE	SIFT		PROVEAN		PolyPhen-2		SNAP2		Mutation Assessor		PANTHER cSNP	
				Sc	Pr	Sc	Pr	Sc	Pr	Sc	Pr	FI Sc	FUNC. IMPACT	Preservation Time (million year)	Pr
IFITM1	rs9667990	C>G	P13A	1	TOL	2.676	Neutral	0.000	BENIGN	EFFECT	29	-1.72	neutral	30	PRB
IFITM1	rs11552361	A>G	N26S	0.101	TOL	-3.129	DLT	0.218	BENIGN	EFFECT	10	1.21	low	30	PRB
IFITM1	rs11552362	C>G	L45V	0.392	TOL	-1.548	Neutral	0.116	BENIGN	NEUTRAL	-49	1.715	low	91	PRB
IFITM1	rs11552366	T>C	I87T	0.026	DLT	-4.579	DLT	0.921	POD	EFFECT	51	3.58	high	456	PRD
IFITM1	rs191154799	G>A	M115I	1	TOL	0.428	Neutral	0.001	BENIGN	NEUTRAL	-10	-0.345	neutral	30	PRB
IFITM1	rs199539158	A>G	H113R	0.349	TOL	-0.401	Neutral	0.218	BENIGN	EFFECT	14	0.55	neutral	30	PRB
IFITM1	rs200518942	G>C	Q120H	0.017	DLT	-1.700	Neutral	0.855	POD	EFFECT	20	2.085	medium	30	PRB
IFITM1	rs200528039	G>A	G74R	0.077	TOL	-7.210	DLT	0.977	PRD	EFFECT	69	1.455	low	456	PRD
IFITM1	rs201082701	G>A	V105I	0.879	TOL	-0.325	Neutral	0.005	BENIGN	NEUTRAL	-10	0.875	low	31	PRB
IFITM1	rs201402251	A>G	H28R	0.444	TOL	0.369	Neutral	0.000	BENIGN	NEUTRAL	-35	0.43	neutral	30	PRB
IFITM1	rs367880644	G>A	E30K	0.095	TOL	-3.412	DLT	0.126	BENIGN	EFFECT	50	1.645	low	324	POD
IFITM1	rs367961349	C>T	H6Y	0.293	TOL	-3.213	DLT	0.009	BENIGN	EFFECT	5	1.33	low	324	POD
IFITM1	rs368479717	A>G	I98V	0.312	TOL	-0.605	Neutral	0.247	BENIGN	NEUTRAL	-37	2.01	medium	324	POD
IFITM1	rs371803538	G>A	V33M	0.159	TOL	-1.889	Neutral	0.884	POD	NEUTRAL	-16	1.465	low	324	POD
IFITM1	rs372454990	G>A	G107S	0.252	TOL	-0.321	Neutral	0.089	BENIGN	EFFECT	18	1.82	low	30	PRB
IFITM1	rs373112031	G>A	V61M	0.11	TOL	-1.932	Neutral	0.956	POD	EFFECT	10	1.795	low	324	POD
IFITM1	rs373832568	G>A	V72M	0.403	TOL	-0.066	Neutral	0.061	BENIGN	EFFECT	6	-0.28	neutral	31	PRB
IFITM1	rs374294080	G>A	V24M	0.174	TOL	-2.081	Neutral	0.631	POD	EFFECT	29	1.245	low	324	POD
IFITM1	rs374941646	G>A	C84Y	0.14	TOL	-9.698	DLT	0.952	POD	EFFECT	47	3.265	medium	324	POD
IFITM1	rs377130310	T>C	L41P	0.024	DLT	-6.476	DLT	0.574	POD	EFFECT	72	3.485	medium	324	POD
IFITM1	rs377178214	C>T	P34S	0.016	DLT	-6.093	DLT	0.998	PRD	EFFECT	60	3.565	high	324	POD
IFITM2	rs14408	T>C	M41T	1	TOL	3.282	Neutral	0.000	BENIGN	EFFECT	24	-1.61	neutral	1	PRB

IFITM2	rs14408	T>C	M21T	1	TOL	-3.445	DLT	0.006	BENIGN	EFFECT	19	0.985	low	1	PRB
IFITM2	rs1058900	T>C	V33A	1	TOL	1.728	Neutral	0.000	BENIGN	EFFECT	24	-0.48	neutral	1	PRB
IFITM2	rs1059091	A>C	I121L	0.103	TOL	-1.002	Neutral	0.000	BENIGN	EFFECT	85	3.185	medium	1	PRB
IFITM2	rs1059091	A>G	I121V	0.13	TOL	-0.322	Neutral	0.000	BENIGN	NEUTRAL	-33	2.215	medium	1	PRB
IFITM2	rs74901761	T>C	F115L	1	TOL	1.008	Neutral	0.000	BENIGN	NEUTRAL	-28	-0.46	neutral	1	PRB
IFITM2	rs75054971	G>A	V53M	0.15	TOL	-2.272	Neutral	0.766	POD	EFFECT	13	1.415	low	325	POD
IFITM2	rs75054971	G>A	V33M	0.161	TOL	-1.078	Neutral	0.574	POD	EFFECT	76	1.545	low	1	PRB
IFITM2	rs183593068	G>A	M116I	0.396	TOL	-1.342	Neutral	0.013	BENIGN	NEUTRAL	-2	1.6	low	1	PRB
IFITM2	rs199693024	T>C	V5A	0.373	TOL	0.039	Neutral	0.038	BENIGN	EFFECT	5	1.935	low	1	PRB
IFITM2	rs201079035	G>A	G14S	0.504	TOL	-1.333	Neutral	0.014	BENIGN	EFFECT	21	0.955	low	1	PRB
IFITM2	rs202139418	A>C	T69P	0.25	TOL	-0.654	Neutral	0.000	BENIGN	EFFECT	49	-0.835	neutral	1	PRB
IFITM2	rs368808923	G>A	E20K	0.128	TOL	-2.779	DLT	0.950	POD	EFFECT	56	2.5	medium	1	PRB
IFITM2	rs369960951	A>G	M30V	1	TOL	1.627	Neutral	0.000	BENIGN	NEUTRAL	-10	-1.82	neutral	1	PRB
IFITM2	rs371179996	A>G	N63S	0.101	TOL	-4.219	DLT	0.986	PRD	EFFECT	16	2.09	medium	456	PRD
IFITM2	rs371346866	G>A	E25K	0.161	TOL	-3.492	DLT	0.218	BENIGN	EFFECT	58	2.445	medium	1	PRB
IFITM2	rs371736596	C>A	P17H	0.063	TOL	-4.344	DLT	0.030	BENIGN	EFFECT	57	2.3	medium	176	PRB
IFITM2	rs373014074	C>G	R132G	0.006	DLT	-0.658	Neutral	0.003	BENIGN	EFFECT	72	0.69	neutral	1	PRB
IFITM2	rs373569657	G>A	M30I	0.236	TOL	0.744	Neutral	0.000	BENIGN	EFFECT	20	0	neutral	1	PRB
IFITM2	rs376286409	G>A	R132Q	0.233	TOL	-0.275	Neutral	0.001	BENIGN	EFFECT	72	-0.41	neutral	1	PRB
IFITM2	rs376647548	G>C	Q26H	1	TOL	4.875	Neutral	0.000	BENIGN	NEUTRAL	-46	-1.425	neutral	1	PRB
IFITM2	rs376647548	G>C	Q6H	1	TOL	-1.691	Neutral	1.000	PRD	EFFECT	18	2.125	medium	1	PRB
IFITM3	rs1136853	G>T	H3Q	0.008	DLT	-2.939	DLT	0.437	BENIGN	EFFECT	76	2.815	medium	97	PRB
IFITM3	rs199582787	C>T	V31M	0.124	TOL	-1.677	Neutral	0.019	BENIGN	EFFECT	2	1.445	low	324	POD
IFITM3	rs199749095	G>T	P70T	0.391	TOL	0.654	Neutral	0.000	BENIGN	NEUTRAL	-1	0.865	low	31	PRB
IFITM3	rs200737925	T>A	H57L	0.005	DLT	-10.664	DLT	0.759	POD	EFFECT	77	3.75	high	324	POD
IFITM3	rs200737925	T>A	H36L	0.006	DLT	-7.090	DLT	0.097	BENIGN	EFFECT	50	3.065	medium	97	PRB
IFITM3	rs368803166	C>G	S50T	0.273	TOL	-2.106	Neutral	0.931	POD	EFFECT	17	2.035	medium	324	POD
IFITM3	rs370158790	G>A	A34V	0.326	TOL	-1.828	Neutral	0.005	BENIGN	EFFECT	10	0.4	neutral	324	POD
IFITM3	rs371741630	C>T	V54M	0.14	TOL	-2.272	Neutral	0.965	PRD	NEUTRAL	-20	2	medium	324	POD
IFITM3	rs376417425	C>T	V90I	0.138	TOL	-0.912	Neutral	1.000	PRD	EFFECT	14	2.645	medium	324	POD

Sc: Score, Pr: Prediction, TOL: Tolerated, DLT: Deleterious, POD: Possibly Damaging, PRD: Probably Damaging.

Table 2. DDG determination of the pathogenic forms of IFITM1, IFITM2, and IFITM3 proteins

GENE	SNP ID	ALLELE CHANGE	AMINO ACID CHANGE	I-Mutant		MUpro		SAAFEC-SEQ	
				DDG (kcal/mol)	Prediction	DDG (kcal/mol)	Prediction	ddG (unit)	Prediction
IFITM1	rs11552366	T>C	I87T	-1.91	Decrease	-2.0309983	Decrease	-1.45	Destabilizing
IFITM1	rs200518942	G>C	Q120H	-0.61	Decrease	-0.59799326	Decrease	-0.04	Destabilizing
IFITM1	rs200528039	G>A	G74R	-0.47	Decrease	-0.1322157	Decrease	-0.93	Destabilizing
IFITM1	rs367880644	G>A	E30K	-0.80	Decrease	-1.0887728	Decrease	-0.09	Destabilizing
IFITM1	rs367961349	C>T	H6Y	0.44	Increase	-0.17753438	Decrease	-0.59	Destabilizing
IFITM1	rs373112031	G>A	V61M	-1.36	Decrease	-0.70976867	Decrease	-0.58	Destabilizing
IFITM1	rs374294080	G>A	V24M	-1.11	Decrease	-0.89921065	Decrease	-0.82	Destabilizing
IFITM1	rs374941646	G>A	C84Y	0.02	Increase	-0.65558741	Decrease	-1.01	Destabilizing
IFITM1	rs377130310	T>C	L41P	-1.54	Decrease	-2.4357497	Decrease	-1.10	Destabilizing
IFITM1	rs377178214	C>T	P34S	-1.67	Decrease	-1.3598958	Decrease	-0.60	Destabilizing
IFITM2	rs75054971	G>A	V53M	-1.13	Decrease	-1.07739	Decrease	-0.36	Destabilizing
IFITM2	rs368808923	G>A	E20K	-0.70	Decrease	-0.98470021	Decrease	-0.76	Destabilizing
IFITM2	rs371179996	A>G	N63S	-0.48	Decrease	-1.0517659	Decrease	-0.26	Destabilizing
IFITM3	rs1136853	G>T	H3Q	-0.19	Decrease	-0.51910301	Decrease	-0.15	Destabilizing
IFITM3	rs200737925	T>A	H57L	0.31	Increase	0.1001401	Increase	-0.10	Destabilizing
IFITM3	rs200737925	T>A	H36L	0.62	Increase	0.69450667	Increase	-0.03	Destabilizing
IFITM3	rs368803166	C>G	S50T	-0.39	Decrease	-0.96036192	Decrease	-0.07	Destabilizing
IFITM3	rs376417425	C>T	V90I	-0.52	Decrease	-0.25157544	Decrease	0.10	Stabilizing

Table 3. Structural analysis of the pathogenic forms of IFITM1, IFITM2, and IFITM3 proteins via HOPE

GENE	SNP ID	ALLELE CHANGE	AMINO ACID CHANGE	WILD TYPE			MUTANT TYPE		
				Size	Charge	Physical State	Size	Charge	Physical State
IFITM1	rs11552366	T>C	I87T	bigger	no information	more hydrophobic	smaller	no information	less hydrophobic
IFITM1	rs200518942	G>C	Q120H	smaller	no information	no information	bigger	no information	no information
IFITM1	rs200528039	G>A	G74R	smaller	neutral	more hydrophobic	bigger	positive	less hydrophobic
IFITM1	rs367880644	G>A	E30K	smaller	negative	no information	bigger	positive	no information
IFITM1	rs367961349	C>T	H6Y	smaller	no information	less hydrophobic	bigger	no information	more hydrophobic
IFITM1	rs373112031	G>A	V61M	smaller	no information	no information	bigger	no information	no information
IFITM1	rs374294080	G>A	V24M	smaller	no information	no information	bigger	no information	no information
IFITM1	rs374941646	G>A	C84Y	smaller	no information	more hydrophobic	bigger	no information	less hydrophobic
IFITM1	rs377130310	T>C	L41P	bigger	no information	no information	smaller	no information	no information
IFITM1	rs377178214	C>T	P34S	bigger	no information	more hydrophobic	smaller	no information	less hydrophobic
IFITM2	rs75054971	G>A	V53M	smaller	no information	no information	bigger	no information	no information
IFITM2	rs368808923	G>A	E20K	smaller	negative	no information	bigger	positive	no information
IFITM2	rs371179996	A>G	N63S	bigger	no information	less hydrophobic	smaller	no information	more hydrophobic
IFITM3	rs1136853	G>T	H3Q	bigger	no information	no information	smaller	no information	no information
IFITM3	rs200737925	T>A	H57L	bigger	no information	less hydrophobic	smaller	no information	more hydrophobic
IFITM3	rs200737925	T>A	H36L	bigger	no information	less hydrophobic	smaller	no information	more hydrophobic
IFITM3	rs368803166	C>G	S50T	smaller	no information	no information	bigger	no information	no information
IFITM3	rs376417425	C>T	V90I	smaller	no information	no information	bigger	no information	no information

Table 4. Homology model validation of the IFITM1, IFITM2, and IFITM3 proteins

I-TASSER Homology models	IFITM1			IFITM2			IFITM3		
	C-score	QMEAN	ERRAT	C-score	QMEAN	ERRAT	C-score	QMEAN	ERRAT
Model 1	-3.19	-8.08	81.1966	-4.14	-14.08	81.4516	-4.04	-14.59	44.8
Model 2	-3.60	-9.43	No result	-4.29	-14.56	39.5161	-4.42	-11.39	77.6
Model 3	-4.53	-9.67	81.1966	-4.78	-11.79	58.871	-4.24	-14.63	61.6
Model 4	-5	-10.18	73.5043	-5	-14.48	58.871	-4.35	-13.78	47.2
Model 5	-4.89	-8.55	85.4701	-4.46	-14.18	44.3548	-4.82	-12.56	68

Table 5. Binding energies of the Spike-IFITM complexes

COMPLEX				COMPLEX			
PROTEIN	LIGAND	SCORE	BINDING FREE ENERGY (kcal/mol)	PROTEIN	LIGAND	SCORE	BINDING FREE ENERGY (kcal/mol)
6VYB	IFITM1 (WILD)	-4947.78	-46.16	6VXX	IFITM1 (P34S)	-5351.80	-39.17
6VYB	IFITM1 (I87T)	-4193.10	-29.14	6VYB	IFITM2 (WILD)	-5753.37	-22.7
6VYB	IFITM1 (Q120H)	-4769.11	-45.65	6VYB	IFITM2 (V53M)	-5899.53	-22.43
6VYB	IFITM1 (G74R)	-4572.53	-23.03	6VYB	IFITM2 (E20K)	-5729.59	-22.35
6VYB	IFITM1 (E30K)	-4866.31	-28.76	6VYB	IFITM2 (N63S)	-5567.96	-25.37
6VYB	IFITM1 (H6Y)	-4868.30	-46.28	6VXX	IFITM2 (WILD)	-4680.82	-26.67
6VYB	IFITM1 (V61M)	-4371.18	-33.43	6VXX	IFITM2 (V53M)	-5046.25	-22.5
6VYB	IFITM1 (V24M)	-5154.42	-38.57	6VXX	IFITM2 (E20K)	-5026.56	-35.48
6VYB	IFITM1 (C84Y)	-4985.04	-45.63	6VXX	IFITM2 (N63S)	-5169.55	-50.77
6VYB	IFITM1 (L41P)	-4494.49	-14.76	6VYB	IFITM3 (WILD)	-4507.06	-31.63
6VYB	IFITM1 (P34S)	-4744.98	-48.25	6VYB	IFITM3 (H3Q)	-4540.09	-30.64
6VXX	IFITM1 (WILD)	-5477.52	-52.42	6VYB	IFITM3 (H57L)	-4651.07	-44.09
6VXX	IFITM1 (I87T)	-4961.61	-31.89	6VYB	IFITM3 (H36L)	-4537.24	-36.28
6VXX	IFITM1 (Q120H)	-4711.17	-20.89	6VYB	IFITM3 (S50T)	-4808.95	-22.31
6VXX	IFITM1 (G74R)	-4579.18	-17.5	6VYB	IFITM3 (V90I)	-5012.83	-42.91
6VXX	IFITM1 (E30K)	-4934.25	-39.43	6VXX	IFITM3 (WILD)	-4757.20	-41.29
6VXX	IFITM1 (H6Y)	-4948.96	-36.16	6VXX	IFITM3 (H3Q)	-5048.03	-33.15
6VXX	IFITM1 (V61M)	-5148.02	-32.58	6VXX	IFITM3 (H57L)	-4766.14	-31.07
6VXX	IFITM1 (V24M)	-5143.98	-32.27	6VXX	IFITM3 (H36L)	-4563.16	-14.48
6VXX	IFITM1 (C84Y)	-4993.99	-31.37	6VXX	IFITM3 (S50T)	-4733.36	4.86
6VXX	IFITM1 (L41P)	-4526.06	-47.08	6VXX	IFITM3 (V90I)	-5153.37	-32.82

Table 6. Numbers of H-bonds, salt bridges and non-bonded contacts of the Spike-IFITM complexes

COMPLEX					COMPLEX				
PROTEIN	LIGAND	No of H-bonds	No of salt bridges	No of non-bonded contacts	PROTEIN	LIGAND	No of H-bonds	No of salt bridges	No of non-bonded contacts
6VYB	IFITM1 (WILD)	2	-	150	6VXX	IFITM1 (P34S)	2	1	143
6VYB	IFITM1 (I87T)	1	1	103	6VYB	IFITM2 (WILD)	2	-	158
6VYB	IFITM1 (Q120H)	2	-	152	6VYB	IFITM2 (V53M)	2	-	160
6VYB	IFITM1 (G74R)	3	1	154	6VYB	IFITM2 (E20K)	-	-	220
6VYB	IFITM1 (E30K)	5	-	147	6VYB	IFITM2 (N63S)	2	-	159
6VYB	IFITM1 (H6Y)	2	-	151	6VXX	IFITM2 (WILD)	-	1	144
6VYB	IFITM1 (V61M)	2	1	191	6VXX	IFITM2 (V53M)	2	-	196
6VYB	IFITM1 (V24M)	8	1	190	6VXX	IFITM2 (E20K)	5	-	188
6VYB	IFITM1 (C84Y)	2	-	152	6VXX	IFITM2 (N63S)	4	1	148
6VYB	IFITM1 (L41P)	7	-	141	6VYB	IFITM3 (WILD)	2	1	131
6VYB	IFITM1 (P34S)	2	-	148	6VYB	IFITM3 (H3Q)	2	1	129
6VXX	IFITM1 (WILD)	1	-	197	6VYB	IFITM3 (H57L)	4	1	296
6VXX	IFITM1 (I87T)	4	-	150	6VYB	IFITM3 (H36L)	3	1	106
6VXX	IFITM1 (Q120H)	4	1	142	6VYB	IFITM3 (S50T)	2	1	223
6VXX	IFITM1 (G74R)	4	-	150	6VYB	IFITM3 (V90I)	4	-	155
6VXX	IFITM1 (E30K)	3	-	223	6VXX	IFITM3 (WILD)	6	4	147
6VXX	IFITM1 (H6Y)	6	2	164	6VXX	IFITM3 (H3Q)	3	-	149
6VXX	IFITM1 (V61M)	3	-	174	6VXX	IFITM3 (H57L)	1	1	210
6VXX	IFITM1 (V24M)	4	-	150	6VXX	IFITM3 (H36L)	2	3	148
6VXX	IFITM1 (C84Y)	-	-	188	6VXX	IFITM3 (S50T)	4	2	149
6VXX	IFITM1 (L41P)	4	2	148	6VXX	IFITM3 (V90I)	3	1	149

Table 7. The positions of the H-bonds and the salt bridges of Spike-IFITM complexes

COMPLEX			COMPLEX		
PROTEIN	LIGAND	RESIDUES BONDED H-BONDS ON PROTEIN-PROTEIN INTERFACE	PROTEIN	LIGAND	RESIDUES BONDED H-BONDS ON PROTEIN-PROTEIN INTERFACE
		SALT BRIDGES (IF THEY EXIST)			SALT BRIDGES (IF THEY EXIST)
6VYB	IFITM1 (WILD)	A:GLN609 <--> B:GLY124 A:GLU 850 <--> B:HIS36	6VXX	IFITM1 (P34S)	A:ASN615 <--> B:THR73 A:ARG616 <--> B: VAL10 A:ASP596 <--> B:ARG66
6VYB	IFITM1 (I87T)	A:TYR723 <--> B:ALA77 A:GLU 930 <--> B:ARG66	6VYB	IFITM2 (WILD)	A:SER254 <--> B:GLU25 A:TYR 256 <--> B:GLU24
6VYB	IFITM1 (Q120H)	A:GLN609 <--> B:GLY124 A:GLU850 <--> B:HIS36	6VYB	IFITM2 (V53M)	A:SER254 <--> B:GLU25 A:TYR 256 <--> B:GLU24
6VYB	IFITM1 (G74R)	A:GLN219 <--> B:GLY124 A:ARG612 <--> B:ASN26 A:THR 828 <--> B:CYS50 A: ARG 612 <--> B: GLU 30	6VYB	IFITM2 (E20K)	-
6VYB	IFITM1 (E30K)	A:CYS522 <--> B:LYS30 A:ARG838 <--> B:THR110 A:ASN842 <--> B:GLN117 A:ASN842 <--> B:THR110 A:THR846 <--> B:HIS113	6VYB	IFITM2 (N63S)	A:SER 254 <--> B:GLU25 A:TYR 256 <--> B:GLU24
6VYB	IFITM1 (H6Y)	A:GLN609 <--> B:GLY124 A:GLU850 <--> B:HIS36	6VXX	IFITM2 (WILD)	- A:LYS366 <--> B:GLU27
6VYB	IFITM1 (V61M)	A: ASN248 <--> B:CYS84 A:THR250 <--> B:GLN76 A: ARG251 <--> B:GLU5	6VXX	IFITM2 (V53M)	A:ARG268 <--> B:ASN68 A:THR 343 <--> B:GLN129
6VYB	IFITM1 (V24M)	A:ASP451 <--> B:ARG 64 A:SER 605 <--> B:THR 23 (2 H-bonds) A:GLN609 <--> B:SER22 A:ARG612<--> B:SER22 A:GLU620 <--> B:TRP39 A:THR828 <--> B:CYS50 (2 H-bonds) A:ASP451 <--> B:ARG64	6VXX	IFITM2 (E20K)	A:ASN244 <--> B:GLN129 A:ARG270 <--> B:ASN63 A:ASN307 <--> B:GLU27 A:TYR309 <--> B:MET30 A: ARG370 <--> B:THR51
6VYB	IFITM1 (C84Y)	A:GLN 609 <--> B:GLY124 A:GLU850 <--> B:HIS36	6VXX	IFITM2 (N63S)	A:ALA1 <--> B:SER42 A:ILE42 <--> B:ARG48 A:LYS77 <--> B:SER13 A:ARG167 <--> B:GLU24 A:ARG167 <--> B:GLU24
6VYB	IFITM1 (L41P)	A:GLN143 <--> B:MET115 A:LEU198 <--> B:ARG66 A:THR482 <--> B:TYR125 A:SER485 <--> B:SER63 (2 H-bonds) A:GLU487 <--> B:SER63, A:VAL488 <--> B:ARG64	6VYB	IFITM3 (WILD)	A:THR594 <--> B:ARG87 A:THR615 <--> B:THR118 A:ASP592 <--> B:LYS104
6VYB	IFITM1 (P34S)	A:GLN609 <--> B:GLY124 A: GLU850 <--> B:HIS36	6VYB	IFITM3 (H3Q)	A:THR594 <--> B:ARG87 A:THR615 <--> B:THR118 A:ASP592 <--> B:LYS104
6VXX	IFITM1 (WILD)	A: THR 834 <--> B: CYS 50	6VYB	IFITM3 (H57L)	A:ASN259 <--> B:ILE128 A:TYR301 <--> B:THR118 A:LYS362 <--> B:GLU28 A:LYS438 <--> B:LYS104 A:LYS362 <--> B:GLU28
6VXX	IFITM1 (I87T)	A:THR258 <--> B:ASN26 (2 H-bonds) A:THR258 <--> B:SER29	6VYB	IFITM3 (H36L)	A:GLN 609 <--> B:SER 50 A:ARG838 <--> B:ASP56 (2 H-bonds)

		A:ARG270 <--> B:GLY53			A:ARG838 <--> B:ASP56
6VXX	IFITM1 (Q120H)	A:ASN35 <--> B:TYR 112	6VYB	IFITM3 (S50T)	A:ASP140 <--> B:TYR80
		A:SER488 <--> B:TYR 125 (2 H-bonds)			A:SER 202 <--> B:GLN97
		A:TYR537 <--> B:TYR125			A:HIS 43 <--> B:GLU28
		A:GLU211 <--> B:ARG66			
6VXX	IFITM1 (G74R)	A:ASN86 <--> B:GLN76 A:ASN86 <--> B:ALA77 A:GLY106 <--> B:THR 81 A:VAL107 <--> B:VAL 105	6VYB	IFITM3 (V90I)	A:ARG251 <--> B:GLN16 A:ASN259 <--> B:GLN16 A:LYS261 <--> B:ASN2 A:ARG366 <--> B:SER61
6VXX	IFITM1 (E30K)	A:GLN613 <--> B:TRP39 A: GLU624 <--> B:CYS50 A:LYS627 <--> B:CYS50	6VXX	IFITM3 (WILD)	A:LYS627 <--> B:GLU25 A:ALA841 <--> B:THR118 A:ARG844 <--> B:TYR20 A:ASN848 <--> B:GLU21 A:LYS863 <--> B:ARG87 A:TYR872 <--> B:GLN97
					A:LYS627 <--> B:GLU25 A:ARG844 <--> B:GLU21 A:ASP866 <--> B:LYS104 A:ARG932 <--> B:ASP92
6VXX	IFITM1 (H6Y)	A:ARG268 <--> B:LYS3 A:ARG270 <--> B:GLY12 A:SER272 <--> B:SER16 A:ASN273 <--> B:THR17 A:TYR309 <--> B:GLU5 A:ARG370 <--> B:GLU7	6VXX	IFITM3 (H3Q)	A:ASP596 <--> B:LYS104 A:THR598 <--> B:ARG87 A:THR619 <--> B:THR118
		A:ARG270 <--> B:GLU 5 A:ARG 370 <--> B:GLU 7			
6VXX	IFITM1 (V61M)	A:THR258 <--> B:ASN 26 A:THR 258 <--> B:SER 29 A:ARG 270 <--> B:GLY 53	6VXX	IFITM3 (H57L)	A:LYS441 <--> B:TYR132
					A:ASP333 <--> B:ARG87
6VXX	IFITM1 (V24M)	A:THR258 <--> B:ASN26 (2 H-bonds) A:THR258 <--> B:SER 29, A:ARG 270 <--> B:GLY 53	6VXX	IFITM3 (H36L)	A:LYS627 <--> B:GLU25 A:ARG864 <--> B:TYR80
					A:LYS627 <--> B:GLU25 A:ASP866 <--> B:LYS104 A:ARG932 <--> B:ASP92
6VXX	IFITM1 (C84Y)	-	6VXX	IFITM3 (S50T)	A:ALA1 <--> B:CYS105 (2 H-Bonds) A:TYR2 <--> B:ASN107 A:THR501 <--> B:SER61
					A:GLU237 <--> B:ARG49 A:GLU502 <--> B:HIS57
6VXX	IFITM1 (L41P)	A:ILE452 <--> B:GLY107 A:GLU842 <--> B:ARG 64 (2 H-bonds)	6VXX	IFITM3 (V90I)	A:ASP 596 <--> B:LYS104 A:THR 598 <--> B:ARG87 A:THR 619 <--> B:THR118
		A:ARG844 <--> B:ARG64 A:ARG844 <--> B:HIS6			A:ASP 596 <--> B:LYS104
		A:ASP775 <--> B:ARG66 A:GLU842 <--> B:ARG 64			

Figure 1. Workflow chart of the study.

Figure 2. Visualization of the 6VYB- IFITM1/2/3 (wild) complexes via BIOVIA Discovery Studio.

Figure 3. Visualization of the 6VXX- IFITM1/2/3 (wild) complexes via BIOVIA Discovery Studio.

Figure 4. Visualization of the 6VYB/6VXX- IFITM1/2/3 (mutant) complexes via BIOVIA Discovery Studio.